Gamida Cell Ltd. financial data

Industry
Biological Products, (No Diagnostic Substances)
Location
5 Nahum Hafzadi Street, Jerusalem, Israel
State of incorporation
Israel
Fiscal year end
December 31
Latest financial report
10-Q - Q1 2024 - May 23, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 133 % -47.6%
Quick Ratio 5.32 %
Return On Equity 527 % -96.7%
Return On Assets -60.2 % +15.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 154M shares +26.7%
Common Stock, Shares, Outstanding 154M shares +87.8%
Entity Public Float 217M USD +110%
Common Stock, Value, Issued 416K USD +87.4%
Weighted Average Number of Shares Outstanding, Basic 153M shares +98.9%
Weighted Average Number of Shares Outstanding, Diluted 153M shares +98.9%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 890K USD
Cost of Revenue 916K USD
Research and Development Expense 18.4M USD -54.3%
General and Administrative Expense 29M USD +24.6%
Costs and Expenses -464K USD +60.4%
Operating Income (Loss) -78.6M USD -4.44%
Nonoperating Income (Expense) 16.6M USD
Net Income (Loss) Attributable to Parent -62M USD +22.6%
Earnings Per Share, Basic 0.13 USD/shares -51.9%
Earnings Per Share, Diluted 0.13 USD/shares -51.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 24.8M USD -47%
Marketable Securities, Current 6.22M USD
Accounts Receivable, after Allowance for Credit Loss, Current 1.03M USD
Inventory, Net 1.97M USD
Assets, Current 33.4M USD -30.7%
Other Long-term Investments 1.29M USD -18.2%
Property, Plant and Equipment, Net 40.2M USD -11.9%
Operating Lease, Right-of-Use Asset 2.78M USD -41.2%
Other Assets, Noncurrent 2.82M USD +123%
Assets 79.6M USD -24.3%
Accounts Payable, Current 5.43M USD +23.5%
Employee-related Liabilities, Current 5.04M USD +16.3%
Liabilities, Current 94.7M USD +325%
Operating Lease, Liability, Noncurrent 1.85M USD -37.9%
Other Liabilities, Noncurrent 1.46M USD -46.9%
Liabilities 98.3M USD
Accumulated Other Comprehensive Income (Loss), Net of Tax -417M USD -23.5%
Retained Earnings (Accumulated Deficit) -500M USD -14.2%
Stockholders' Equity Attributable to Parent -18.7M USD -21.9%
Liabilities and Equity 79.6M USD -24.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -23M USD -3.2%
Net Cash Provided by (Used in) Financing Activities 1.33M USD -74.5%
Net Cash Provided by (Used in) Investing Activities -89K USD +89.2%
Common Stock, Shares Authorized 325M shares +117%
Common Stock, Shares, Issued 154M shares +87.7%
Common Stock, Par or Stated Value Per Share 0.01 ILS/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -21.8M USD -21.7%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 24.8M USD -47%
Interest Paid, Excluding Capitalized Interest, Operating Activities 2.3M USD +4.45%
Deferred Tax Assets, Valuation Allowance 46.6M USD +17.8%
Deferred Tax Assets, Gross 46.9M USD +16.8%
Operating Lease, Liability 2.98M USD
Depreciation 1.13M USD +966%
Payments to Acquire Property, Plant, and Equipment 89K USD -89.2%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -31.7M USD -70.7%
Lessee, Operating Lease, Liability, to be Paid 3.12M USD -43.2%
Property, Plant and Equipment, Gross 46.1M USD -5.48%
Operating Lease, Liability, Current 1.14M USD -45.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 683K USD -44.5%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.04M USD -49.3%
Operating Lease, Weighted Average Discount Rate, Percent 0.03 pure -29.3%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 136K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 520K USD -46.5%
Deferred Tax Assets, Operating Loss Carryforwards 42.1M USD +23.7%
Lessee, Operating Lease, Liability, to be Paid, Year Four 525K USD -25.4%
Share-based Payment Arrangement, Expense 3.86M USD +11.6%